Munich-based industrial holding ADCURAM has sold its subsidiary Nuvisan Pharma Holding GmbH effective 12 December 2014. The new owners are a highly regarded Southern German family office and the management team led by Dr. Dietrich Bruchmann. ADCURAM has thus now also sold the early-phase business, having successfully divested the late-phase branch to Japanese investor Linical in November 2014.

Nuvisan is a mid-sized contract research organisation headquartered in Neu-Ulm, Germany. It is the leading European laboratory for bioanalytical laboratory services in clinical studies and runs a 65-bed clinic for Phase I clinical studies in addition to its lab activities. Nuvisan has some 200 employees.

TRACC LEGAL already advised ADCURAM in the year 2010 during the acquisition of the NUVISAN Group as well as during the divestment of the late phase branch to Linical.

The comprehensive legal advice regarding the divestment of Nuvisans’ clinical and Phase I business to a family office and the management was rendered by Dr. Thomas Lotz and Dr. Thorsten Steinhaus from TRACC LEGAL.